Abstract 954P
Background
The combination of PD-1 blockades with antiangiogenic drugs is the main therapeutic regimen for advanced hepatocellular carcinoma (HCC). Radiotherapy has generally been used to treat HCC with improved long-term outcome. The combination of radiotherapy and other therapies is considered to be a promising treatment for HCC. The objective of this study is to investigate the feasibility and safety of radiotherapy combined with tislelizumab plus anlotinib in advanced HCC.
Methods
In this single-center, open-label, phase II clinical trial, 45 patients(pts) with previously untreated, advanced HCC, with an age ranging from 18-75 years old, and an ECOG performance status ≤ 1 were planned to be enrolled. According to mRECIST efficacy evaluation criteria, the efficacy was evaluated by enhanced CT or MRI. RTOG/EORTC criteria was used to evaluate radiation-induced liver injury. Requirements for radiotherapy planning were D95% ≥14.2-46 Gy and ≥12.5-40 Gy for GTV and CTV, respectively. The patients underwent treatment with tislelizumab (200 mg, Q3W) plus anlotinib (8 mg, Q3W), and radiotherapy until disease progression or intolerance. The primary endpoints were ORR and OS, the secondary endpoints were PFS, DCR and safty.
Results
At data cut-off date of Feb 2023, 45 pts (44 males and 1 female) were enrolled with a median age of 51.5 years (range: 26-75). Of whom, 4 pts achieved complete response, 22 pts obtained partial response, 8 pts were stable disease, illustrating an ORR of 57.8% (95%CI 42.2-72.3) and a DCR of 75.6% (95%CI 60.5-87.1). The median PFS was 7.8 months (95%CI 5.8-9.8). The rate of treatment emerged adverse events (TEAEs) on grade 1/2 were 82.2%, and grade 3/4 were 13.3% (6/45). No grade 5 or radiation-induced liver disease were observed.
Conclusions
Radiotherapy combined with tislelizumab plus anlotinib demonstrated promising efficacy and tolerable safety profile in the treatment of advanced HCC. And this study was still ongoing and further follow-up was required to obtain final survival results subsequently.
Clinical trial identification
ChiCTR2000039022.
Editorial acknowledgement
Legal entity responsible for the study
the affiliated hospital of southwest medical university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18